Celgene Corp (NASDAQ:CELG)

CAPS Rating: 5 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.


Player Avatar JohnStuartMill (61.58) Submitted: 2/28/2013 8:39:53 AM : Outperform Start Price: $49.74 CELG Score: +4.76

Cash strong company (3.9B) with new revenue pipelines (Pomalyst, Apremilast, Abraxane (new apps) replacing Revlimid.

Featured Broker Partners